Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Biotech firm Amgen is disputing the claims, which relate to how it accounts for profits from its Puerto Rico operations.

Amgen Falls After Revealing a $7 Billion IRS Tax Bill

Amgen Inc. (NASDAQ:AMGN ) Q1 2022 Results Conference Call April 27, 2022 5:00 PM ET Company Participants Arvind Sood - VP, IR Bob Bradway - Chairman and CEO Peter Griffith - CFO Murdo Gordon - EVP, Global Commercial Operations David Reese - EVP, Research and Development Conference Call Participants Michael Yee - Jefferies Jay Olson - Oppenheimer Goeff Meacham - Bank of America Salveen Richter - Goldman Sachs Matthew Harrison - Morgan Stanley Yaron Werber - Cowen & Company Umer Raffat - Evercore ISI Carter Gould - Barclays Robyn Karnauskas - Truist Mohit Bansal - Wells Fargo Dane Leone - Raymond James Evan Seigerman - BMO Capital Markets Gavin Scott - JPMorgan Colin Bristow - UBS Operator My name is RJ, and I will be your conference facilitator today for Amgen's First Quarter 2022 Financial Results Conference Call. All lines have been placed on mute to prevent any background nose.

Amgen Inc. (AMGN) CEO Bob Bradway on Q1 2022 Results - Earnings Call Transcript

Amgen (AMGN) delivered earnings and revenue surprises of 0.71% and 2.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Surpasses Q1 Earnings and Revenue Estimates

Amgen Inc. on Wednesday logged better-than-expected revenue and a decline in profit in the first quarter.

Amgen Q1 revenue beats expectations, profit declines

Amgen Inc on Wednesday said the U.S. Internal Revenue Service (IRS) is seeking additional back taxes of $5.1 billion, plus interest and penalties, related to the drugmaker's 2013 to 2015 accounting for profits between the United States and Puerto Rico, the location of most of its manufacturing operations.

Amgen says IRS seeks another $5.1 billion in back taxes

THOUSAND OAKS, Calif. , April 27, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2022.

AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS

Studies Showed Sustained Reduction in LDL-C With no new Safety Findings The Combined Studies Evaluated Safety and Tolerability of Repatha in More Than 6,600 Patients for Over Five Years After Completing the Phase 3 FOURIER Trial Repatha is the Longest Studied PCSK9i THOUSAND OAKS, Calif. , April 27, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER cardiovascular outcomes trial.

AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)

Molecular Partners AG

Shares of Molecular Partners Inc. MOLN, -36.67% slid 37.3% in premarket trading on Wednesday, the day after the company said Amgen Inc. AMGN, -0.91% returned the global rights to an investigational oncology therapy currently in a Phase 1 clinical trial targeting solid tumors. Amgen's stock was up 0.3% in the premarket on Wednesday.

Molecular Partners shares tumble 37% after Amgen returns rights to tumor treatment candidate

Molecular Partners AG's (NASDAQ: MOLN) collaborating partner Amgen Inc (NASDAQ: AMGN) for MP0310 (AMG 506) will return the global rights of MP0310 to Molecular Partners following a strategic pipeline review.  MP0310 is a dual-targeted compound targeting both FAP.

Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen

Biogen

Corcept Therapeutics

Harmony Biosciences Holdings

Incyte

Regeneron Pharmaceuticals

Bio-Techne

Biotech stocks were some of the best performers at the start of the pandemic. More recently, though, they've vastly underperformed the broader market.

7 Best Biotech Stocks to Build Your Portfolio

AbbVie

McDonald's

NRG Energy

Procter & Gamble

Target

Walmart

Americans will still use brand names, buy groceries and clothes, get healthcare services and pay their utilities during a recession. That's good news for these 7 recession-resistant stocks to buy.

What Stocks to Buy That Should Do Well in a Recession — Our 7 Top Picks

PepsiCo

You would be hard-pressed to find more-solid companies.

These 2 Nasdaq Stocks Are Favorites Among Defensive Investors

Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Amgen (AMGN) Might Surprise This Earnings Season

Chevron

Coca-Cola

Merck

Visa

Five Dow stocks with positive Earnings ESP will report earnings results this week. These are: V, Ko, MRK, CVX and AMGN.

5 Blue-Chip Stocks Likely to Gain on Earnings Results This Week

THOUSAND OAKS, Calif. , April 22, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Wednesday, April 27, 2022, after the close of the U.S. financial markets.

AMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS

Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others and the biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Is a Beat Likely for Amgen (AMGN) This Earnings Season?

Bank of New York Mellon

Kraft Heinz

Verizon

If any investor has stood the test of time, it is Warren Buffett, and with good reason.

Why 5 of Warren Buffett's Highest-Yielding Stocks May Be the Best 2022 Ideas Now

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?

Amgen Q4 2022 revenue was up 3% y/y. Cancer therapy Lumakras is a new revenue driver.

Amgen's Cancer Portfolio And Pipeline Make It A Buy

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Initial data from a late-stage study comparing Amgen's (AMGN) Stelara biosimilar candidate with the original Stelara drug showed no clinically meaningful differences in treating plaque psoriasis.

Amgen's (AMGN) Stelara Biosimilar Meets Psoriasis Study Goal

CrowdStrike

Walgreens

Here are three of the best long-term stocks to invest in with tax refunds this year The post Want to Invest Your Tax Refund? 3 Long-Term Stocks to Consider appeared first on InvestorPlace.

Want to Invest Your Tax Refund? 3 Long-Term Stocks to Consider

Primary Efficacy Analysis Demonstrates no Clinically Meaningful Differences Compared to STELARA THOUSAND OAKS, Calif. , April 18, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA® (ustekinumab) in adult patients with moderate to severe plaque psoriasis.

AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)

Dividend growth investors tend to favor the health care sector as this area of the economy is much more resistant to recessionary pressures than most. Health care products and services remain in demand during economic downturns as people seek to maintain or improve their quality of life.

Amgen's Dividend Can Weather Any Storm

American Campus Communities

Saul Centers

CONSOL Energy

Corteva Inc

DT Midstream

General Mills

National Fuel Gas

Public Service Enterprise Group

Valero Energy

The stock market is under pressure but there are always opportunities. Thirteen stocks in S&P 1500 have strong momentum and rising volume.

News for Amgen Stock (AMGN)